We are live on ! Find out more
LLY icon

Eli Lilly

1,179 hedge funds and large institutions have $66B invested in Eli Lilly in 2016 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 435 increasing their positions, 428 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 58

50% more funds holding in top 10

Funds holding in top 10: 2436 (+12)

27% more call options, than puts

Call options by funds: $818M | Put options by funds: $643M

11% more capital invested

Capital invested by funds: $59.4B → $66B (+$6.56B)

2% more funds holding

Funds holding: 1,1511,179 (+28)

2% more repeat investments, than reductions

Existing positions increased: 435 | Existing positions reduced: 428

1.1% less ownership

Funds ownership: 77.03%75.93% (-1.1%)

Holders
1,179
Holders Change
+28
Holders Change %
+2.43%
% of All Funds
31.46%
Holding in Top 10
36
Holding in Top 10 Change
+12
Holding in Top 10 Change %
+50%
% of All Funds
0.96%
New
97
Increased
435
Reduced
428
Closed
58
Calls
$818M
Puts
$643M
Net Calls
+$175M
Net Calls Change
-$99.1M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
26
UBS AM
Illinois
$424M +$6.36M +84,469 +2%
TCIM
27
TIAA CREF Investment Management
New York
$412M -$87.2M -1,158,108 -18%
PI
28
Putnam Investments
Massachusetts
$376M +$30.3M +402,175 +9%
BA
29
BlackRock Advisors
Delaware
$371M +$2.1M +27,887 +0.6%
Legal & General Group
30
Legal & General Group
United Kingdom
$370M -$4.17M -55,363 -1%
APG Asset Management
31
APG Asset Management
Netherlands
$357M +$18M +239,179 +6%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$350M +$16.9M +224,295 +5%
Fidelity Investments
33
Fidelity Investments
Massachusetts
$313M -$203M -2,701,240 -40%
Lazard Asset Management
34
Lazard Asset Management
New York
$304M -$10.9M -145,428 -4%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$303M +$83.6M +1,110,376 +41%
LCOV
36
London Company of Virginia
Virginia
$296M +$14.1M +187,801 +5%
Deutsche Bank
37
Deutsche Bank
Germany
$264M +$67.2M +892,012 +36%
Swiss National Bank
38
Swiss National Bank
Switzerland
$256M +$14.8M +196,000 +6%
BlackRock
39
BlackRock
New York
$245M +$35.5M +471,063 +18%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$241M +$12.7M +169,331 +6%
Charles Schwab
41
Charles Schwab
California
$227M -$1.43M -18,969 -0.7%
Sumitomo Mitsui Trust Group
42
Sumitomo Mitsui Trust Group
Japan
$225M -$1.12M -14,830 -0.5%
Neuberger Berman Group
43
Neuberger Berman Group
New York
$222M -$58.3M -774,308 -22%
Morgan Stanley
44
Morgan Stanley
New York
$221M -$43.6M -579,569 -17%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$203M -$12.3M -163,000 -6%
CCM
46
Causeway Capital Management
California
$202M +$45.9M +609,341 +38%
US Bancorp
47
US Bancorp
Minnesota
$188M -$347K -4,605 -0.2%
BIM
48
BlackRock Investment Management
Delaware
$187M +$802K +10,658 +0.5%
UBS Group
49
UBS Group
Switzerland
$186M -$18M -239,423 -9%
Mitsubishi UFJ Trust & Banking
50
Mitsubishi UFJ Trust & Banking
Japan
$184M +$18.1M +240,987 +12%

LLY Hedge Fund Activity: Q2 2016 in Review

1,179 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q2 2016, worth a combined $66B — up 11% from $59.4B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new LLY positions and 58 closed out — a net gain of 39 holders — while 435 added to existing stakes and 428 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $299M. The largest seller was Royal London Asset Management, cutting an estimated $1.29B.

  • 1,179 institutional investors held Eli Lilly (LLY) as of Q2 2016, up from 1,151 in Q1 2016.
  • Funds reported $66B of Eli Lilly stock for Q2 2016, up 11% quarter-over-quarter.
  • 97 funds opened new Eli Lilly positions in Q2 2016 and 58 closed out, a net change of +39 holders.
  • The largest Eli Lilly buyer in Q2 2016 was Goldman Sachs, an estimated $299M added.
  • The largest Eli Lilly seller in Q2 2016 was Royal London Asset Management, an estimated $1.29B sold.

Based on aggregated 13F filings for Q2 2016.